FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated Unresectable or Metastatic HER2-positive Biliary Tract Cancer By Ogkologos - December 17, 2024 171 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the HERIZON-BTC-01 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR How to Cope With Waiting Periods During Cancer: An Expert Perspective June 1, 2023 New study to detect oesophageal cancer earlier April 28, 2022 Genetic Mechanisms Identified for Acquired Resistance to Non-Covalent BTK Inhibitors March 28, 2022 First-of-its-kind app for patients on clinical trials being piloted by Cancer... November 28, 2022 Load more HOT NEWS Smoking Initiation Shifting from Teens to Young Adults Women Experience More Side Effects from Pelvic Radiation than Realized Intercontinental Asian Study Compiles the Relative Incidence of non-Hodgkin T-cell Lymphoma... How Do Black People with Cancer View Clinical Research?
